ReviewInternational journal of radiation oncology, biology, physics2019
A Current Review of Spatial Fractionation: Back to the Future?
Review in International journal of radiation oncology, biology, physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980259 (Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma), which is not on this map. Cited by 96 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter，Prospective, Phase II, Randomized Controlled Trial
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it, 158 citations in OpenAlex.
- Spatially fractionated radiation therapy for bulky tumors: a systematic review of clinical outcomes and dosimetric challenges.Radiation oncology (London, England) · 2026Pooled it
- Bibliometric analysis of global research trends in spatially fractionated radiotherapy.Frontiers in oncology · 2026Pooled it
- On the significance of the different geometrical and dosimetric parameters in microbeam and minibeam radiation therapy a retrospective evaluation.Frontiers in oncology · 2024Pooled it
- Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers.Frontiers in oncology · 2021Pooled it
- Stage IIIB pulmonary sarcomatoid carcinoma treated with spatially fractionated radiotherapy combined with antiangiogenic therapy and sequential chemo-immunotherapy: A case report.Oncology letters · 2026Article
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Proton pencil beam scanning lattice radiotherapy: technical implementation and comparison against photon-based delivery.The British journal of radiology · 2026Article
- Megavoltage photon minibeam production through the embedded multi-leaf collimator of a clinical linac: A dosimetric characterization.Medical physics · 2026Article
- Roadmap for the implementation of particle minibeam therapy.Medical physics · 2026Review
- Surviving Cancer, Lacking Support: The Hidden Burden of Modern Radiation Oncology in the Treatment of Oligometastatic Disease.Cancers · 2026Review
- Development and validation of an automated evaluation system for lattice radiotherapy using a commercial treatment planning system scripting API.Journal of applied clinical medical physics · 2026Article
- A multidisciplinary experimental and methodological investigation of electron and proton minibeams in the framework of the INFN MIRO project.Medical physics · 2026Article
- A dosimetric study of photon energy and flattening filter mode combinations in Stereotactic Central Ablative Radiotherapy.Journal of applied clinical medical physics · 2026Article
- A Comparative Analysis of Virtual 2D VMAT-Based SFRT and 3D Lattice Radiotherapy: Evaluation of Dosimetric and Therapeutic Outcomes.Journal of biomedical physics & engineering · 2026Article
- Article
- Spiral volumetric modulated arc therapy enhances peak-to-valley dose contrast for 3D-GRID radiotherapy compared to VMAT and tomotherapy.BMC cancer · 2026Article
- A novel strategy for soft tissue sarcoma lattice radiotherapy: integrating X-ray andγ-ray technologies to optimize dose delivery.Radiation oncology (London, England) · 2026Article
- Spatially Modulated Irradiation Alters Extracellular Vesicle MicroRNA Cargo in Rat Glioma and Astrocyte Models.Molecular neurobiology · 2026Article
- Radiobiotherapy in Osteosarcoma: A State-Based Educational Framework for Strategy Selection and Trial Design.Current oncology (Toronto, Ont.) · 2026Review
- Spatially fractionated radiation therapy (SFRT): a scoping review of dosimetric and biological evidence supporting a valley dose-driven translational framework.Radiation oncology (London, England) · 2026Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Spatially fractionated radiation therapy represents a significant departure from canonical thinking in radiation oncology despite having origins in the early 1900s. The original and most common implementation of spatially fractionated radiation therapy uses commercially available blocks or multileaf collimators to deliver a nonconfluent, sieve-like pattern of radiation to the target volume in a nonuniform dose distribution. Dosimetrically, this is parameterized by the ratio of the valley dose in cold spots to the peak dose in hot spots, or the valley-to-peak dose ratio. The radiobiologic mechanisms are postulated to involve radiation-induced bystander effects, microvascular alterations, and/or immunomodulation. Current indications include bulky or locally advanced disease that would not be amenable to conventional radiation or that has proved refractory to chemoradiation. Early-phase clinical trials have shown remarkable success, with some response rates >90% and minimal toxicity. This has promoted technological developments in 3-dimensional formats (LATTICE), micron-size beams (microbeam), and proton arrays. Nevertheless, more clinical and biological data are needed to specify ideal dosimetry parameters and to formulate robust clinical indications and guidelines for optimal standardized care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.